EGFR and non-small cell lung carcinoma: The efficacy of TKIs with and without WBRT has not been determined in patients with BM resulting from EGFR-mutated NSCLC; thus, we aimed at identifying optimal therapeutic strategies for patients with BM in the setting of dominant oncogenic-driven disease.